title: Curcumin analogue A501 induces G2/M arrest and apoptosis in non-small cell lung cancer cells.
abstract: Curcumin and its analogues have been reported to exert anti-cancer activity against a variety of tumors. Here, we reported A501, a new curcumin analogue. The effect of A501 on cell viability was detected by MTT assay, the result showed that A501 had a better inhibiting effect on the four non-small cell lung cancer (NSCLC) cells than that of curcumin. Moreover, Colony forming experiment showed A501 significant restrained cell proliferation. Flow cytometry displayed A501 can cause G2/M arrest and induce apoptosis. Western blotting showed that A501 decreased the expression of cyclinB1, cdc-2, bcl-2, while increased the expression of p53, cleaved caspase-3 and bax. In conclusion, curcumin analogues A501 played antitumor activity by inhibiting cell proliferation and inducing apoptosis of NSCLC cells. And it was likely to be a promising starting point for the development of curcumin-based anticancer drugs.
authors.affiliation: Chemical Biology Research Center, College of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China E-mail : jinrongjrjr@163.com, wjzwzmu@163.com.
authors.forename: Yi-Qun
authors.initials: YQ
authors.lastname: Xia
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Wei
authors.forename: Wu-Lan
authors.initials: WL
authors.lastname: Li
authors.forename: Karvannan
authors.initials: K
authors.lastname: Kanchana
authors.forename: Chao-Chao
authors.initials: CC
authors.lastname: Xu
authors.forename: Da-Hui
authors.initials: DH
authors.lastname: Chen
authors.forename: Pei-Hong
authors.initials: PH
authors.lastname: Chou
authors.forename: Rong
authors.initials: R
authors.lastname: Jin
authors.forename: Jian-Zhang
authors.initials: JZ
authors.lastname: Wu
authors.forename: Guang
authors.initials: G
authors.lastname: Liang
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D016203:CDC2 Protein Kinase; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D053148:Caspase 3 / Q000096:biosynthesis; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003474:Curcumin / Q000031:analogs & derivatives / Q000494:pharmacology*; D056744:Cyclin B1 / Q000096:biosynthesis; D018844:Cyclin-Dependent Kinases / Q000096:biosynthesis; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D059566:M Phase Cell Cycle Checkpoints / Q000187:drug effects*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis; D051028:bcl-2-Associated X Protein / Q000096:biosynthesis
chemical_list: D000970:Antineoplastic Agents; C494826:BAX protein, human; C534699:CCNB1 protein, human; D056744:Cyclin B1; D019253:Proto-Oncogene Proteins c-bcl-2; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D051028:bcl-2-Associated X Protein; D016203:CDC2 Protein Kinase; C528899:CDK1 protein, human; D018844:Cyclin-Dependent Kinases; D053148:Caspase 3; D003474:Curcumin